Home Cart Sign in  
Chemical Structure| 1985606-14-1 Chemical Structure| 1985606-14-1

Structure of Baloxavir marboxil
CAS No.: 1985606-14-1

Chemical Structure| 1985606-14-1
Product Citations

Alternative Products

Product Details of Baloxavir marboxil

CAS No. :1985606-14-1
Formula : C27H23F2N3O7S
M.W : 571.55
SMILES Code : O=C(OC)OCOC(C(C=C1)=O)=C(N1N([C@@H]2C3=CC=CC=C3SCC4=C(F)C(F)=CC=C24)[C@@]5([H])N6CCOC5)C6=O
MDL No. :MFCD31619272
InChI Key :RZVPBGBYGMDSBG-GGAORHGYSA-N
Pubchem ID :124081896

Safety of Baloxavir marboxil

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Madin-Darby canine kidney (MDCK) cells 0.01–1000 nM 2–3 days Assess virus sensitivity to baloxavir acid and determine IC50 values PMC7184910
MDCK-SIAT1 cells 0.6 nM 24 hours To evaluate the inhibitory effect of Baloxavir on influenza viruses, results showed significant inhibition of influenza virus by Baloxavir. PMC9426601
Madin-Darby canine kidney (MDCK) cells 4 nM 24 hours To evaluate the inhibitory effect of BXA on A(H7N9) virus replication, results showed that BXA at 4 nM significantly reduced virus titers by 1.5-2.8 log. PMC6401108

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Ferrets Influenza virus infection model Subcutaneous injection 4 mg/kg Single dose To evaluate the efficacy of Baloxavir alone or in combination with Oseltamivir in treating influenza virus infection, results showed that combination therapy reduced the selection of resistant viruses. PMC9426601
BALB/c mice Lethal influenza virus A/PR/8/34 infection model Oral gavage 0.5, 1.5, 15 or 50 mg/kg Twice daily for 5 days To evaluate the efficacy of delayed oral dosing (96 h post-infection) of baloxavir marboxil alone or in combination with oseltamivir phosphate in a lethal influenza virus infection Mice model. Results showed that baloxavir marboxil monotherapy (15 or 50 mg/kg twice daily) significantly and dose-dependently reduced virus titre 24 h after administration and completely prevented mortality, whereas oseltamivir phosphate monotherapy was less effective. Combination therapy (baloxavir marboxil 0.5 mg/kg + oseltamivir phosphate 10 mg/kg) provided additional efficacy compared with monotherapy in terms of virus-induced mortality, elevation of cytokine/chemokine levels, and pathological changes in the lung. PMC6376846
Nude mice (BALB/c-nu/nu) Immunocompromised Mice model infected with influenza virus Oral 10 mg/kg Once daily for 28 days Evaluate therapeutic efficacy in immunocompromised hosts, prolonged survival time but failed to clear the virus PMC7184910
Ferrets Influenza A virus-infected ferret model Oral 10 and 30 mg/kg Twice daily for 1 day To evaluate the antiviral effects of baloxavir marboxil against influenza A virus infection. Results showed that baloxavir marboxil significantly reduced virus titers and improved body temperature changes when administered at Day 1 post-infection. PMC7578299
BALB/c mice H5N1 highly pathogenic avian influenza virus infection model Oral gavage 0.5, 5, or 50 mg/kg Twice daily for 1 or 5 days To evaluate the therapeutic effects of BXM on H5N1 highly pathogenic avian influenza virus infection, results showed that BXM significantly reduced viral titers and improved survival rates PMC8777714
BALB/c mice Highly pathogenic H7N9 virus infection model Oral 1.5, 15, or 50 mg/kg Once or twice daily for 5 days To evaluate the therapeutic efficacy of baloxavir marboxil in mice infected with highly pathogenic H7N9 virus. Results showed that a single 15 mg/kg dose was sufficient to protect mice, and 5-day treatment significantly suppressed virus replication in respiratory organs. PMC6893572
BALB/c mice A/Anhui/1/2013 (H7N9) lethal infection model Oral 5 and 50 mg/kg Twice a day for 5 days To evaluate the protective efficacy of BXM against A(H7N9) lethal infection, results showed that BXM at 5 and 50 mg/kg completely protected mice from lethal infection and significantly reduced lung virus titers by 2-3 log. PMC6401108

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.75mL

0.35mL

0.17mL

8.75mL

1.75mL

0.87mL

17.50mL

3.50mL

1.75mL

References

 

Historical Records

Categories